Background: Hypertension remains a healthcare problem in South Africa. When prescribing evidence-based, cost-effective anti-hypertensive treatment, guideline adherence is essential. The Joint National Committee's Sixth Report (JNC VI) built its evidence-based review on the outcome of clinical trials. The objective of this study was to assess the hypertension guideline adherence of general practitioners in private practice and of primary health care physicians in an academic government hospital setup in Pretoria, using the JNC VI guidelines.
Introduction
Hypertension is one of the major diseases in South Africa. 1 Health care costs and medical insurance payments are high and increasing, and lifelong treatment, especially with the newer anti-hypertensive drugs, could prove very expensive. 1 It is therefore important that health care providers in both public and private setup follow guidelines when prescribing anti-hypertensive treatment, focusing on evidencebased cost-effective treatment. 1, 2 The JNC VI, published in 1997, built its evidence-based review on knowledge from clinical trials and represents a consensus of expert opinion where evidence is lacking. [3] [4] [5] The JNC VI report did not formally consider cost when recommending treatment guidelines, but a previous analysis suggested that low dose diuretics as the recommended first line of treatment for uncomplicated hypertension also proved to be the most cost effective. 6 Studies on the prescribing patterns of health care physicians have shown that some physicians lack detailed knowledge of hypertension guidelines and tend to prescribe more expensive drugs without evidence of efficacy. 1, 4, 5 Currently available studies on guideline adherence in hypertension have been done on private practitioners, internal physicians and cardiologists, in either a public or a private setup, but to the best of my knowledge no survey has been done on primary care physicians in both private and public setups in Pretoria. [1] [2] [3] [4] [5] 7, 8 The principle aim of this study was to assess the hypertension guideline adherence of general practitioners in private practice and in an academic government hospital setting in Pretoria. The JNC VI report, published in 1997, was used as the treatment guideline. 9 The survey also assessed the most prescribed generic drug in each antihypertensive drug group. Primary health care physicians (n = 32) 56. 4 1990 Due to missing values, this analysis was calculated using 98 observations. Mean percentage correct answers = total amount of correct answers/total amount of questions answered Table I for the responses of each study group.
Method
Anti-hypertensive treatment in co-morbid conditions (See Table II for a breakdown of the responses of the two study populations.) In response to the question, "Name initial choice of anti-hypertensive drug in a post-myocardial infarction (MI) patient with hypertension and atrial fibrillation", 62.5% of the respondents correctly selected beta-blockers, while 21.2% selected an ACE inhibitor.
An ACE inhibitor was correctly selected by 81.9% of the respondents in response to the question "Select initial drug choice in patients with hypertension and diabetic nephropathy". Most respondents (70.4%) correctly chose ACE inhibitors as the drug of choice in patients with hypertension complicated by congestive cardiac failure (CCF).
Only 27.3% of all participants correctly chose a nondihydropyridine calcium-channel blocker (CCB) as a choice when treating a hypertensive patient with angina unreceptive to beta-blockers and nitrates. Most respondents (41.4%) chose a dihydropyridine calcium-channel blocker, and 22.2% of the respondents selected an ACE inhibitor.
In response to the question, "Name oral drug choice when treating a pregnant female with newly diagnosed hypertension", 68.4% of the respondents correctly chose a centralacting alpha-2 agonist.
Most participants (60.2%) were correct in selecting a low-dose thiazide diuretic when treating isolated systolic hypertension.
In treating a patient with left ventricular dysfunction and ACE inhibitor intolerance, 56.6% of the respondents correctly chose an angiotensin II antagonist.
An ACE inhibitor was correctly selected by 48.1% of the respondents as the treatment choice in a hypertensive patient with renal insufficiency, while 21.7% chose a low dose thiazide diuretic.
For each clinical scenario, the respondents named their most prescribed drug in the chosen antihypertensive drug class. The results are presented in Table III .
All the participants qualified in South Africa. See Table IV for the mean percentage of correct answers and their correlation with the year of qualification.
Only 27.8% (p < 0.0001) of the respondents answered seven or more questions correctly, and 69.44% of all the participating medical doctors received more than 50% (p < 0.0001) for the questionnaire. More primary health care physicians (40%; p = 0.23) than general practitioners (21.9%; p < 0.0001) had more than seven answers correct. When comparing the guideline adherence of the two groups, the Likelihood Ratio Chi-Square test (p = 0.053), and Fisher's Exact tests (p = 0.066) suggested, but did not conclude, a significant difference. This might have been more significant had the public setup sample size been larger. No participant scored 100% for the questionnaire.
Discussion
This survey showed that general practitioners in private practice and primary heath care physicians in the three academic hospitals in Pretoria did not adhere to the hypertension guidelines suggested by the JNC VI report. It is important to note that the results of the ALLHAT study (December 2002), as well as the new JNC 7 report (21 May 2003) were published at the time of this survey, which might have influenced some of the answers of the questionnaire. 11, 12 However, the guidelines suggested by the JNC VI report will be used for the purposes of the study and reference will be made to any new information.
Several trials proved diuretics to be superior in the prevention of cardiovascular morbidity and mortality associated with hypertension. [9] [10] [11] [12] [13] [14] The JNC VI and 7 reports recommend diuretics to be used as first-line antihypertensive drug in the treatment of uncomplicated hypertension and ISH. 9, 11 Despite this, nearly 40% of all the participants in the study preferred other anti-hypertensive drugs in the treatment of ISH, which suggests that diuretics still remain underused in the treatment of hypertension.
The JNC VI and 7 reports specify compelling indications and comorbidities that justify the use of specific anti-hypertensive drug treatments, using evidence from previous clinical trials. 9, 11 For example, the benefit of treating patients with
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Original Research acute coronary syndrome with betablockers has been proven, but only 62.5% of all respondents chose to prescribe these drugs to a patient with a previous MI complicated by atrial fibrillation. 4, 9, 10 Furthermore, 14.4% of the doctors chose calcium channel blockers as their first choice in treating post-MI patients, even though this is not recommended by either report. 9, 11 Both JNC reports recommend that, unless contraindicated, patients with diabetic and non-diabetic renal disease should receive an ACE inhibitor to inhibit disease progression. 9, 11, 15 While more than 80% of the participants prescribe these drugs to patients with diabetic nephropathy, only 48% of the respondents prescribe ACE inhibitors for patients with mild renal insufficiency. [9] [10] [11] Another compelling indication for the use of ACE inhibitors is CCF. [9] [10] [11] It has been proven that drugs from this drug class significantly reduce morbidity and mortality in patients with heart failure. [9] [10] [11] 16 Most respondents (70.4%) followed this recommendation.
The JNC VI report suggests that angiotensin II antagonists should be used in some co-morbid conditions when ACE inhibitors are indicated but not tolerated. 9 Only 56.6% of the respondents prefer Angiotensin II antagonists when treating left ventricular dysfunction in a hypertensive patient with ACE inhibitor intolerance.
The majority of respondents knew the definition of hypertension, though 20.6% of the physicians diagnosed hypertension as BP >130/>85 mmHg, which is classified as "high-normal" in the JNC VI report. However, the largest group of participants (44.7%) incorrectly defined ISH as SBP >160 mmHg and DBP <90 mmHg.
Due to the small population of participating doctors in the government hospital setup, the main purpose of this survey was not to compare the two study populations. Even so, there seems to be no significant difference between the choice of answer to each question, as well as the mean percentage of correct answers, in the two study populations. Also, the year of qualification seemed to have no effect on the mean percentage of correct answers (see Table IV ).
Limitations
The size of the study population of both groups is very small, which could make the percentages misleading. New guidelines have recently been implemented that might change old perspectives. There seems to be a difference in guideline adherence (>70% for correct answers) between the two study groups, but this could be misleading, as this calculation was done without taking missing values into account. Also, the questions were asked in broad way, which might be interpreted differently in a clinical setup.
Conclusions
This survey suggested that physicians in private and public practice do not adhere to guidelines when prescribing anti-hypertensive medication. Diuretics are still underused when initiating antihypertensive treatment, but most physicians adhere to guidelines when treating a hypertensive patient with CCF, ischaemic heart disease and diabetic nephropathy. Future studies on large sample sizes, representing both general practitioners and public doctors, before and after a degree of intervention (e.g. conference on hypertension guidelines) might proof more valuable.
